• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于人I型干扰素的新型灵敏且具选择性的生物测定法。

A novel sensitive and selective bioassay for human type I interferons.

作者信息

Files J G, Gray J L, Do L T, Foley W P, Gabe J D, Nestaas E, Pungor E

机构信息

Berlex Laboratories, Inc., Richmond, CA 94804-0099, USA.

出版信息

J Interferon Cytokine Res. 1998 Dec;18(12):1019-24. doi: 10.1089/jir.1998.18.1019.

DOI:10.1089/jir.1998.18.1019
PMID:9877444
Abstract

We describe a novel MxA gene-induction assay for type I interferons (IFN-alpha and IFN-beta) based on the specific induction of the MxA gene in cultured human cells. Accumulated intracellular MxA protein is determined by immunologic measurement by a rapid method using commercially available materials. IFN activity can be measured accurately over a concentration range of 0.1-30 IU/ml. In contrast, type II IFN and other cytokines are not significantly detected. The MxA-induction assay has advantages in terms of specificity, reliability, and sensitivity over other methods for assaying type I IFN. It has also been adapted and validated for measuring the titers of anti-IFN-beta neutralizing antibodies in human sera.

摘要

我们描述了一种基于培养的人类细胞中Mx A基因的特异性诱导来检测I型干扰素(IFN-α和IFN-β)的新型Mx A基因诱导检测方法。通过使用市售材料的快速方法进行免疫测定来确定细胞内积累的Mx A蛋白。在0.1-30 IU/ml的浓度范围内可以准确测量IFN活性。相比之下,未显著检测到II型IFN和其他细胞因子。与其他检测I型IFN的方法相比,Mx A诱导检测方法在特异性、可靠性和灵敏度方面具有优势。它也已被改编并验证用于测量人血清中抗IFN-β中和抗体的滴度。

相似文献

1
A novel sensitive and selective bioassay for human type I interferons.一种用于人I型干扰素的新型灵敏且具选择性的生物测定法。
J Interferon Cytokine Res. 1998 Dec;18(12):1019-24. doi: 10.1089/jir.1998.18.1019.
2
Regulation of IFN-alpha/beta, MxA, 2',5'-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells.甲型流感病毒感染的人肺上皮细胞中IFN-α/β、MxA、2',5'-寡腺苷酸合成酶及HLA基因表达的调控
J Immunol. 1997 Mar 1;158(5):2363-74.
3
A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.一种用于测定抗β-1b干扰素中和抗体的新型生物测定法。
J Interferon Cytokine Res. 1998 Dec;18(12):1025-30. doi: 10.1089/jir.1998.18.1025.
4
Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.通过测量MxA启动子激活来定量不同的人α干扰素亚型和聚乙二醇化干扰素活性。
Antimicrob Agents Chemother. 2005 Sep;49(9):3770-5. doi: 10.1128/AAC.49.9.3770-3775.2005.
5
Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.一种基于实时PCR的生物测定法的开发与验证,用于定量检测抗人干扰素-β的中和抗体。
J Immunol Methods. 2007 Apr 10;321(1-2):19-31. doi: 10.1016/j.jim.2006.12.012. Epub 2007 Feb 20.
6
The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene.近端干扰素刺激反应元件对干扰素反应至关重要:抗病毒Mx A基因的启动子分析
J Interferon Cytokine Res. 1998 Sep;18(9):773-81. doi: 10.1089/jir.1998.18.773.
7
Control of IFN-inducible MxA gene expression in human cells.人类细胞中干扰素诱导的Mx A基因表达的调控
J Immunol. 1993 Mar 1;150(5):1715-26.
8
Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.
J Interferon Cytokine Res. 1999 Mar;19(3):243-51. doi: 10.1089/107999099314171.
9
Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology.病因不明的慢性病患者外周血中抗病毒MxA蛋白水平升高。
J Med Virol. 2001 Oct;65(2):301-8. doi: 10.1002/jmv.2034.
10
Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.
J Interferon Cytokine Res. 2007 Aug;27(8):637-42. doi: 10.1089/jir.2006.0131.

引用本文的文献

1
Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.确定评估生物治疗药物中和抗体反应的检测形式的策略。
AAPS J. 2016 Nov;18(6):1335-1350. doi: 10.1208/s12248-016-9954-6. Epub 2016 Aug 5.
2
Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.使用基于 MxA 蛋白标准化测量的检测方法来验证针对干扰素-β的中和抗体评估检测方法。
J Interferon Cytokine Res. 2013 Nov;33(11):660-71. doi: 10.1089/jir.2012.0079. Epub 2013 Jul 13.
3
Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
干扰素 β-1b 诱导的中和抗体检测和定量的变异性。
J Neuroinflammation. 2012 Jun 15;9:129. doi: 10.1186/1742-2094-9-129.
4
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.多发性硬化症干扰素优化研究:对疗效欠佳者使用375微克β-1b干扰素
J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.
5
A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.一项针对多发性硬化症患者中干扰素β-1b中和抗体影响的病例研究,该研究对患者进行了为期3年的每月一次影像学随访。
Clin Exp Immunol. 2007 Oct;150(1):61-7. doi: 10.1111/j.1365-2249.2007.03467.x. Epub 2007 Jul 30.
6
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24.
7
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement.青少年皮肌炎外周血单个核细胞中MxA基因表达:与肌肉受累的关联
Clin Immunol. 2006 Sep;120(3):319-25. doi: 10.1016/j.clim.2006.05.011. Epub 2006 Jul 21.
8
A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.一种用于评估抗干扰素β抗体临床相关性的灵敏放射免疫沉淀测定法。
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1236-9. doi: 10.1136/jnnp.74.9.1236.
9
In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses.用α/β干扰素和病毒刺激后牛细胞中Mx基因产物的体外和体内检测
Clin Diagn Lab Immunol. 2002 Nov;9(6):1192-9. doi: 10.1128/cdli.9.6.1192-1199.2002.